CryoCell Stock Based Compensation from 2010 to 2024

CCEL Stock

USD 8.67 0.42 4.62%

CryoCell International Stock Based Compensation yearly trend continues to be quite stable with very little volatility. The value of Stock Based Compensation is projected to decrease to about 616.4 K. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2002-11-30

Previous Quarter

178.1 K

Current Value

145.9 K

Quarterly Volatility

235.2 K

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Selling General Administrative of 11.2 M or Total Revenue of 18.4 M, as well as many indicators such as Price To Sales Ratio of 1.56, Dividend Yield of 0.2 or Days Sales Outstanding of 79.26. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.

Check out the analysis of CryoCell International Correlation against competitors.

For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.

Latest CryoCell International's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of CryoCell International over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. CryoCell International's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CryoCell International's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

CryoCell Stock Based Compensation Regression Statistics

	Arithmetic Mean	668,305
	Geometric Mean	517,019
	Coefficient Of Variation	66.34
	Mean Deviation	331,131
	Median	602,978
	Standard Deviation	443,321
	Sample Variance	196.5B
	Range	1.7M
	R-Value	0.03
	Mean Square Error	211.4B
	R-Squared	0.001
	Significance	0.91
	Slope	3,114
	Total Sum of Squares	2.8T

CryoCell Stock Based Compensation History

	2024	616.4 K
	2023	939.1 K
	2022	816.6 K
	2021	461.3 K
	2020	301.6 K
	2019	622.1 K
	2018	397.8 K

Other Fundumenentals of CryoCell International

Stock Based Compensation To Revenue

CryoCell International Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Short Term Debt	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Treasury Stock	Net Tangible Assets	Capital Surpluse	Long Term Investments	Good Will	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.1	0.57	-0.03	0.74	0.88	0.97	0.32	0.5	0.61	-0.27	0.87	0.72	0.81	0.67	-0.07	-0.59	0.91	-0.32	0.35	0.63	0.7	-0.49	0.78
Total Stockholder Equity	0.1		-0.45	0.78	-0.42	-0.28	-0.13	-0.05	0.6	0.08	-0.38	-0.08	-0.2	-0.02	-0.26	0.33	0.26	0.08	0.24	0.49	-0.01	0.48	-0.04	-0.02
Net Debt	0.57	-0.45		-0.28	0.69	0.57	0.67	0.02	0.0	0.3	0.01	0.53	0.66	0.75	0.33	-0.1	-0.81	0.51	-0.22	-0.02	0.35	0.21	-0.37	0.58
Retained Earnings	-0.03	0.78	-0.28		-0.44	-0.35	-0.21	-0.07	0.29	0.25	-0.5	-0.19	-0.13	-0.12	-0.46	-0.02	0.2	0.07	-0.04	0.05	0.17	0.28	0.12	-0.12
Accounts Payable	0.74	-0.42	0.69	-0.44		0.78	0.85	-0.01	0.0	0.14	0.02	0.7	0.53	0.82	0.51	-0.2	-0.68	0.61	-0.31	0.05	0.23	0.07	-0.63	0.83
Net Receivables	0.88	-0.28	0.57	-0.35	0.78		0.94	0.46	0.21	0.64	-0.12	0.84	0.69	0.65	0.79	-0.23	-0.49	0.85	-0.33	0.19	0.69	0.53	-0.32	0.65
Total Liab	0.97	-0.13	0.67	-0.21	0.85	0.94		0.32	0.35	0.57	-0.18	0.88	0.75	0.82	0.72	-0.14	-0.65	0.89	-0.36	0.24	0.62	0.57	-0.49	0.8
Total Current Assets	0.32	-0.05	0.02	-0.07	-0.01	0.46	0.32		0.11	0.68	0.04	0.35	0.47	-0.19	0.5	-0.17	0.13	0.45	-0.28	0.14	0.69	0.53	0.63	-0.1
Intangible Assets	0.5	0.6	0.0	0.29	0.0	0.21	0.35	0.11		0.35	-0.36	0.42	0.44	0.29	0.34	0.02	-0.36	0.39	-0.1	0.23	0.27	0.78	-0.32	0.27
Short Term Debt	0.61	0.08	0.3	0.25	0.14	0.64	0.57	0.68	0.35		-0.3	0.57	0.65	0.16	0.56	-0.34	-0.18	0.75	-0.46	0.0	0.97	0.77	0.18	0.14
Short Term Investments	-0.27	-0.38	0.01	-0.5	0.02	-0.12	-0.18	0.04	-0.36	-0.3		-0.2	-0.14	-0.19	-0.02	0.17	0.13	-0.31	0.25	0.01	-0.24	-0.34	0.19	-0.18
Common Stock	0.87	-0.08	0.53	-0.19	0.7	0.84	0.88	0.35	0.42	0.57	-0.2		0.81	0.67	0.87	-0.15	-0.54	0.93	-0.34	0.29	0.52	0.59	-0.43	0.78
Long Term Debt	0.72	-0.2	0.66	-0.13	0.53	0.69	0.75	0.47	0.44	0.65	-0.14	0.81		0.49	0.7	-0.27	-0.74	0.78	-0.4	-0.01	0.62	0.59	-0.17	0.54
Property Plant Equipment	0.81	-0.02	0.75	-0.12	0.82	0.65	0.82	-0.19	0.29	0.16	-0.19	0.67	0.49		0.35	0.08	-0.74	0.64	-0.06	0.33	0.19	0.33	-0.76	0.89
Current Deferred Revenue	0.67	-0.26	0.33	-0.46	0.51	0.79	0.72	0.5	0.34	0.56	-0.02	0.87	0.7	0.35		-0.19	-0.31	0.74	-0.37	0.18	0.52	0.54	-0.21	0.45
Treasury Stock	-0.07	0.33	-0.1	-0.02	-0.2	-0.23	-0.14	-0.17	0.02	-0.34	0.17	-0.15	-0.27	0.08	-0.19		0.2	-0.14	0.62	0.73	-0.36	0.05	-0.02	0.05
Net Tangible Assets	-0.59	0.26	-0.81	0.2	-0.68	-0.49	-0.65	0.13	-0.36	-0.18	0.13	-0.54	-0.74	-0.74	-0.31	0.2		-0.46	0.17	0.12	-0.21	-0.26	0.59	-0.64
Capital Surpluse	0.91	0.08	0.51	0.07	0.61	0.85	0.89	0.45	0.39	0.75	-0.31	0.93	0.78	0.64	0.74	-0.14	-0.46		-0.33	0.33	0.71	0.7	-0.3	0.72
Long Term Investments	-0.32	0.24	-0.22	-0.04	-0.31	-0.33	-0.36	-0.28	-0.1	-0.46	0.25	-0.34	-0.4	-0.06	-0.37	0.62	0.17	-0.33		0.53	-0.49	-0.15	0.03	-0.07
Good Will	0.35	0.49	-0.02	0.05	0.05	0.19	0.24	0.14	0.23	0.0	0.01	0.29	-0.01	0.33	0.18	0.73	0.12	0.33	0.53		-0.05	0.42	-0.11	0.34
Short Long Term Debt	0.63	-0.01	0.35	0.17	0.23	0.69	0.62	0.69	0.27	0.97	-0.24	0.52	0.62	0.19	0.52	-0.36	-0.21	0.71	-0.49	-0.05		0.7	0.18	0.15
Net Invested Capital	0.7	0.48	0.21	0.28	0.07	0.53	0.57	0.53	0.78	0.77	-0.34	0.59	0.59	0.33	0.54	0.05	-0.26	0.7	-0.15	0.42	0.7		-0.04	0.27
Net Working Capital	-0.49	-0.04	-0.37	0.12	-0.63	-0.32	-0.49	0.63	-0.32	0.18	0.19	-0.43	-0.17	-0.76	-0.21	-0.02	0.59	-0.3	0.03	-0.11	0.18	-0.04		-0.69
Capital Stock	0.78	-0.02	0.58	-0.12	0.83	0.65	0.8	-0.1	0.27	0.14	-0.18	0.78	0.54	0.89	0.45	0.05	-0.64	0.72	-0.07	0.34	0.15	0.27	-0.69

Click cells to compare fundamentals

About CryoCell International Financial Statements

CryoCell International investors utilize fundamental indicators, such as Stock Based Compensation, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	939.1 K	616.4 K
Stock Based Compensation To Revenue	0.03	0.03

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:

How To Invest In CryoCell

Details

Is CryoCell Stock a good investment?

Details

What is CryoCell International's Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of CryoCell International Correlation against competitors.

For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.625

Earnings Share

(1.07)

Revenue Per Share

3.89

Quarterly Revenue Growth

0.025

Return On Assets

(0)

The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

CryoCell Stock Based Compensation from 2010 to 2024

Latest CryoCell International's Stock Based Compensation Growth Pattern

CryoCell Stock Based Compensation Regression Statistics

CryoCell Stock Based Compensation History

Other Fundumenentals of CryoCell International

CryoCell International Stock Based Compensation component correlations

About CryoCell International Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY